Carlos Paya V - 09 Nov 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Director
Signature
Carlos V. Paya, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
09 Nov 2023
Net transactions value
$0
Form type
4
Filing time
09 Nov 2023, 16:36:46 UTC
Previous filing
16 Jun 2023
Next filing
10 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Gift $0 -3,125 -56% $0.000000 2,500 09 Nov 2023 Direct F1, F2
transaction PCVX Common Stock Award $0 +3,125 $0.000000 3,125 09 Nov 2023 By Family Trust F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Gift $0 -30,000 -100% $0.000000* 0 09 Nov 2023 Common Stock 30,000 $22.02 Direct F1, F4
transaction PCVX Stock Option (right to buy) Gift $0 +30,000 $0.000000 30,000 09 Nov 2023 Common Stock 30,000 $22.02 By Family Trust F1, F4, F5
transaction PCVX Stock Option (right to buy) Gift $0 -18,750 -100% $0.000000* 0 09 Nov 2023 Common Stock 18,750 $22.70 Direct F1, F6
transaction PCVX Stock Option (right to buy) Gift $0 +18,750 $0.000000 18,750 09 Nov 2023 Common Stock 18,750 $22.70 By Family Trust F1, F5, F6
transaction PCVX Stock Option (right to buy) Gift $0 -15,000 -100% $0.000000* 0 09 Nov 2023 Common Stock 15,000 $53.08 Direct F1, F7
transaction PCVX Stock Option (right to buy) Gift $0 +15,000 $0.000000 15,000 09 Nov 2023 Common Stock 15,000 $53.08 By Family Trust F1, F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person.
F2 As previously disclosed in Reporting Person's Form 4 filed on June 15, 2023, this represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F3 Shares are held directly by a trust for the sole benefit of the Reporting Person.
F4 Option vests over 36 months, 1/3 of which will vest on October 27, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
F5 Options are held directly by a trust for the sole benefit of the Reporting Person.
F6 The shares of Common Stock subject to the option vested fully on June 1, 2023.
F7 The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.